Improving Adherence to Oral Therapy for Cancer: The Role of the HCP
|
|
- Elvin Sims
- 6 years ago
- Views:
Transcription
1 Improving Adherence to Oral Therapy for Cancer: May 3, 2016 Held in conjunction with the AOSW Annual Conference Tampa, Florida CLL: Update on Treatment and Side Effects Management Welcome and Introductions Lauren Berger, MPH Senior Director The Leukemia & Lymphoma Society Professional Education & Engagement Rye Brook, NY 1
2 Faculty Cara Kondaki, LCSW, CBPN-IC, OSW-C Department of Oncology Cleveland Clinic Florida Weston, FL Lisa Nodzon, PhD, ARNP, AOCNP Department of Malignant Hematology Moffitt Cancer Center Tampa, FL Jennifer Powers, PharmD Senior Manager, Oncology Disease State Walgreen Co. Deerfield, IL Disclosures Lisa Nodzon, PhD, ARNP, AOCNP is on the Speakers Bureau for Ariad, Gilead, Novartis, and Pfizer. She is also a Consultant for Ariad & Gilead. Jennifer Powers, PharmD does not have any relevant financial relationships with any commercial interests to disclose. Cara Kondaki, LCSW, CBPN-IC, OSW-C does not have any relevant financial relationships with any commercial interests to disclose. 2
3 Oral Adherence for Optimal CML Management Lisa Nodzon, PhD, ARNP, AOCNP Department of Malignant Hematology Moffitt Cancer Center Tampa, FL Decline in Deaths Related to Ph+ CML Since the Utilization of TKIs 1. American Cancer Society (ACS). Cancer Facts & Figures 2001.Atlanta, GA: ACS, Inc., ACS. Cancer Facts & Figures Atlanta, GA: ACS, Inc., ACS. Cancer Facts and Figures Atlanta, GA: ACS, Inc., ACS. Cancer Facts and Figures Atlanta, GA: ACS, Inc., ACS. Cancer Facts & Figures Atlanta, GA: ACS, Inc., ACS. Cancer Facts and Figures Atlanta, GA: ACS, Inc., ACS. Cancer Facts and Figures Atlanta, GA: ACS, Inc., ACS. Cancer Facts & Figures Atlanta, GA: ACS, Inc., ACS. Cancer Facts & Figures Atlanta, GA: ACS, Inc., ACS. Cancer Facts and Figures Atlanta, GA: ACS, Inc., ACS. Cancer Facts & Figures Atlanta, GA: ACS, Inc., Kantarjian H et al. Blood. 2012;119(9):
4 Probability of MMR Probability of CMR 7/1/2016 Poor Overall Survival for CML Patients that Progress to Blast Crisis Despite TKI Therapy Even with Imatinib Treatment Median OS in Blast Crisis ~9 mos. BC, blast crisis; OS, overall survival; TKI, tyrosine kinase inhibitor. Hehlmann R. Blood. 2012;25(4): Reproduced with permission of AMERICAN SOCIETY OF HEMATOLOGY in the format - republish in presentation/slides via Copyright Clearance Center. Long-term Adherence to Imatinib is Critical for Achieving Molecular Response Adherence to Imatinib monitored for 3 mos in 87 consecutive CML patients with CCyR using microelectronic monitoring devices 1.0 MMR Adherence > 90% (n = 64) Adherence 90% (n = 23) 1.0 CMR Adherence > 90% (n = 64) Adherence 90% (n = 23) 0.8 P < P = Mos Since Start of Imatinib Therapy Mos Since Start of Imatinib Therapy Marin D, et al. J Clin Oncol. 2010;28:
5 % Days With Correct Number of Bottle Openings 7/1/2016 Adherence Rates and Dosing Frequency Several meta-analyses have suggested that less frequent dosing was associated with greater adherence 1-4 * Adapted from Saini, et al. 1 In the bar graph above, study populations comprised adult patients with chronic diseases taking oral medications for various disease conditions: hypertension, dyslipidemia, type 2 diabetes mellitus, asthma, seizure disorder, congestive heart failure, migraine headaches, and stable angina. * In one of the four meta-analyses, Claxton et al (2001) compared compliance rates and dosing frequency and discovered no significant differences between once-daily and twice-daily dosing. 4 Statistically significant (P<0.05) between once daily and other doses specified. 1. Saini SD, et al. Am J Manag Care. 2009;15(6):e22-e Iskedjian M, et al. Clin Ther. 2002;24(2): Parienti JJ, et al. Clin Infect Dis. 2009;48(4): Claxton AJ, et al. Clin Ther. 2001;23(8): Specific Factors Affecting Patient Adherence With Oral Oncology Therapies Disease Treatment Chronic conditions Severity of symptoms Complexity of regimen Asymptomatic disease Number of daily doses Duration of therapy Lack of immediate benefit Actual/perceived side effects Impact on lifestyle Patient Knowledge of disease/treatment Perceived benefit of treatment Fear of side effects Psychological impairment Motivation Socioeconomic Healthcare System Low health literacy Lack of family/social support Access to pharmacy/facilities Medication cost Lack of healthcare insurance Poor HCP-patient relationship Poor HCP communication skills Lack of positive reinforcement Lack of knowledge on adherence HCP=healthcare practitioner. Moore S. J Adv Pract Oncol. 2010;1:
6 Predictors of Poor Adherence Patient s lack of insight into the illness Poor providerpatient relationship Presence of barriers to care or medications Missed appointments Complexity of treatment Cost of medication, copayment, or both Major Predictors of Poor Adherence Patient s lack of belief in benefit of treatment Side effects of medication Inadequate follow- up or discharge planning Treatment of asymptomatic disease Presence of cognitive impairment Presence of psychological problems, particularly depression Financial Toxicity and Adherence Barriers Jennifer Powers, PharmD Senior Manager, Oncology Disease State Walgreen Co. Deerfield, IL 6
7 Navigation Through Insurance is Complex Insurance Challenges Commercially insured Medicare / Medicaid Requires multiple prior authorizations Continued follow-up Appeals & off-label use Defining Financial Toxicity Objective Direct costs associated with treatment Subjective Financial concerns resulting from high treatment costs De Souza J, The ASCO Post. 2015, 6 7
8 Financial Toxicity has Multiple Impacts to Patient Outcomes Qualityof- life Treatment compliance Survival Financial Toxicity A Correlation Between Bankruptcy in the Cancer Patient and Mortality Data suggests cancer patients are 2.5 times more likely to become bankrupt than people without cancer The adjusted hazard ratio for mortality in cancer patients who become bankrupt is 1.79 (95% CL { }; P<.001) Associations persisted even after excluding patients with distant-stage disease at diagnosis Bansal A, Ramsey SD, Feorenko Cr, et al. Journal of Clinical Oncology. 2015;34: ASCO Abstract
9 Financial Toxicity in Insured Patients with Multiple Myeloma 100 Multiple Myeloma Patients At least minor financial burden 71 Borrowed money to pay for medication 21 Utilized savings to pay for treatment 46 Applied for financial assistance 36 Higher than expected costs for tx 59 Huntington S, et al. The Lancet Haematology. 2015;2 Discussing Financial Toxicity with Cancer Patients The time is now, especially with oral cancer treatments routinely over $10K per month Consider financial toxicity s impact on patients health-related quality of life and not simply on costs associated with treatment Patients must be given the tools and resources to discuss the side effects of financial toxicity as they would other side effects related to cancer treatment Ubel PA, Abemethy AP, Zafar SY. New England Journal of Medicine. 2013;369:
10 Psychosocial Factors Affecting Adherence to Oral Cancer Therapies Cara Kondaki, LCSW, CBPN-IC, OSW-C Department of Oncology Cleveland Clinic Florida Weston, FL Psychosocial Factors Affecting Adherence to Oral Cancer Therapies Cost-co-pays, not on formulary, lack of insurance Taking multiple medications Multiple chronic conditions 10
11 Psychosocial Factors Affecting Adherence to Oral Cancer Therapies Education and Literacy Cultural Differences Belief Systems Side effects and Quality of Life Issues Because patients with cancer self-administer oral chemotherapy, they typically do not receive the same amount of teaching and monitoring as patients receiving IV chemotherapy. Patient education is vital to promote patient safety, optimal dosing, and adherence to the treatment plan. Hartigan, K. Clinical Journal of Oncology Nursing. Nov/Dec 2003 Supplement, Vol. 7 Issue 6, p Psychosocial Factors Affecting Adherence to Oral Cancer Therapies Depression and anxiety Substance abuse/smoking Lack of access to mental health support Support system or lack of 11
12 Strategies that May Be Effective for Long-term Adherence National Comprehensive Cancer Network (NCCN ): Strategies to Improve Adherence Careful explanation of the importance of adherence 1 Direct questioning of patients during office visits 1 Follow-up appointments to review side effects 2 Adequate and appropriate side effect management 2 Cochrane literature review of over 69 RCTs suggests strategies that may be effective 3 Reinforcement Manual telephone follow-up Counseling More Frequent Interaction with the Patient Reminders Financial Toxicity Selfmonitoring RCT=randomized controlled trials. Crisis Intervention Psychological therapy 1. NCCN Clinical Practice Guidelines in Oncology : Breast Cancer V NCCN Clinical Practice Guidelines in Oncology : Chronic Myelogenous Leukemia V Haynes RB, et al. Cochrane Database Syst Rev. 2008;(2):CD Myeloma Oral Adherence Information & Resources: 12
13 The Leukemia & Lymphoma Society (LLS) offers: Patient education programs: Patient videos: Free education materials: The Leukemia & Lymphoma Society (LLS) offers: Information Resource Center: Speak with an Information Specialist who can assist patients and HCPs through cancer treatment, including clinical trial searches, and financial and social challenges. TOLL-FREE PHONE: (800) Live, Online Chats moderated by oncology SWs provide forum for patients to share experiences: What to ask: Lists of questions for patients to ask the healthcare team. Share question guides with your patients: LLS Online Social Network for HCPs and patients to seek answers and share information: CommunityView.LLS.org 13
14 The Leukemia & Lymphoma Society (LLS) offers: Continuing education programs and videos - offer free continuing education credit: Question & Answer Session 14
Welcome & Introductions. Questions to Ask to. Treatment Decisions
Make Informed Treatment Decisions Welcome & Introductions Make Informed Treatment Decisions Gail J. Roboz, MD Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell
More informationWelcome and Introductions
Living with Chronic Myeloid Leukemia Welcome and Introductions Living with Chronic Myeloid Leukemia Living with Chronic Myeloid Leukemia (CML) Neil P. Shah, MD, PhD Edward S. Ageno Distinguished Professor
More informationWelcome and Introductions
Information for Patients With Acute Myeloid Leukemia (AML) Welcome and Introductions Information for Patients With Acute Myeloid Leukemia (AML) Mark B. Juckett, MD Vice Chair for Clinical Affairs and Quality
More information9/26/2018. Learning Objectives
ADVANCES IN CHRONIC MYELOID LEUKEMIA Alison Wakoff Loren, MD, MSCE Associate Professor of Medicine Director, Blood & Marrow Transplantation Vice Chair, Faculty Development Department of Medicine Perelman
More informationChronic Myeloid Leukemia A Disease of Young at Heart but Not of Body
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,
More informationIn this program you will learn
1 In this program you will learn How to gather information to help you make treatment decisions Questions to ask about the benefits and risks of any treatment How new blood cancer treatments are developed
More information10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD Dalia Khan 1, Noemi Roy 1, Vasha Bari 1, Grant Vallance 1, Helene Dreau 1, Timothy Littlewood 1, Andrew Peniket 1, Paresh Vyas
More informationClinical Breakthroughs & Challenges In Hematologic Malignancies
Clinical Breakthroughs & Challenges In Hematologic Malignancies Saturday, January 19, 2013 Disney s Grand Floridian Resort Lake Buena Vista, Florida COURSE DIRECTOR CONFERENCE CONTACT Melissa.Pearson@Moffitt.org
More informationPatient Adherence Claire Neely, MD
Patient Adherence Claire Neely, MD Care of Mental, Physical, and Substance use Syndromes! The project described was supported by Grant Number 1C1CMS331048-01-00 from the Department of Health and Human
More informationDUPLICATION DISTRIBUTION PROHIBBITED AND. Utilizing Economic and Clinical Outcomes to Eliminate Health Disparities and Improve Health Equity
General Session IV Utilizing Economic and Clinical Outcomes to Eliminate Health Disparities and Improve Health Equity Accreditation UAN 0024-0000-12-012-L04-P Participation in this activity earns 2.0 contact
More informationAddressing the Problem of Health Literacy: Practical Approaches in Practice
Addressing the Problem of Health Literacy: Practical Approaches in Practice Darren DeWalt, MD, MPH & Michael Pignone, MD, MPH University of North Carolina-Chapel Hill Department of Medicine Topics Relationship
More informationFrom the Clinic to Home: The Shift to Oral Oncolytic Therapy
From the Clinic to Home: The Shift to Oral Oncolytic Therapy Eric Vachon, BSN, RN Michigan State University, College of Nursing Disclosure I do not have anything to disclose. Objectives Oral oncolytics
More informationLiving with Hairy Cell Leukemia. Michael Grever, MD Professor Emeritus, Internal Medicine/Hematology The Ohio State University Columbus, OH
Living with Hairy Cell Leukemia Michael Grever, MD Professor Emeritus, Internal Medicine/Hematology The Ohio State University Columbus, OH Living with Hairy Cell Leukemia Introduction to Hairy Cell Leukemia
More informationStopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase
More informationHematologic Malignancies 2013 Retrospective Study at Truman Medical Center
Hematologic Malignancies 2013 Retrospective Study at Truman Medical Center Kristen Strasser, MD & Abdulraheem Qasem, MD Introduction: Hematologic Malignancies includes malignant diseases of the bone marrow
More informationImproving Medication Adherence through Collaboration between Colleges of Pharmacy and Community Pharmacies
Improving Medication Adherence through Collaboration between Colleges of Pharmacy and Community Pharmacies Megan Willson, PharmD, BCPS; Catrina Schwartz, PharmD, BS; Jennifer Robinson, PharmD Spokane,
More informationManagement of CML in blast crisis. Lymphoma Tumor Board November 27, 2015
Management of CML in blast crisis Lymphoma Tumor Board November 27, 2015 Chronic Phase CML - 2. Peter Maslak, ASH Image Bank 2011; 2011-2455 Copyright 2011 American Society of Hematology. Copyright restrictions
More informationLow doses of tyrosine kinase inhibitors in CML
CML Horizons Conference Warsaw 4-6 May 2018 Low doses of tyrosine kinase inhibitors in CML Delphine Rea, MD, PhD Pôle Hématologie Oncologie Radiothérapie INSERM UMR-1160 Centre Hospitalo-Universitaire
More informationFinancial Hardship in Cancer Survivors
Financial Hardship in Cancer Survivors Robin Yabroff Robin.yabroff@hhs.gov The views expressed are those of the speaker and do not necessarily represent the official position of Department of Health and
More informationShaping our future: a call to action to tackle the diabetes epidemic and reduce its economic impact
Shaping our future: a call to action to tackle the diabetes epidemic and reduce its economic impact Task Force for the National Conference on Diabetes: The Task Force is comprised of Taking Control of
More informationCML and Future Perspective. Hani Al-Hashmi, MD
CML and Future Perspective Hani Al-Hashmi, MD Objectives Learning from CML history Outcome of interest to clinician Patient and community interest!! Learning from CML history Survival Probability (All
More informationEMERGING THERAPIES FOR BLOOD CANCERS:
EMERGING THERAPIES FOR BLOOD CANCERS: Case Studies Adherence, Ethics and Other Nursing Management Challenges CONTINUING EDUCATION IS OFFERED FOR THIS ACTIVITY CONTENTS Welcome.............................................................
More informationEvaluating Cost-Effectiveness in Later-line Chronic Myeloid Leukemia (CML): Ponatinib in the Third-Line Treatment of CML in Canada
Evaluating Cost-Effectiveness in Later-line Chronic Myeloid Leukemia (CML): Ponatinib in the Third-Line Treatment of CML in Canada Jeffrey H. Lipton, Sergio Iannazzo, Silvia Chiroli, Lisa McGarry 06 CADTH
More informationImproving Adherence to Chronic Medications: The Physicians Role and How 340b Can Help
Improving Adherence to Chronic Medications: The Physicians Role and How 340b Can Help William Shrank MD MSHS Division of Pharmacoepidemiology & Pharmacoeconomics Harvard Medical School wshrank@partners.org
More informationPatient Intake Assessment Tools for Navigation
Patient Intake Assessment Tools for Navigation Review and utilize the following with new patient referrals to the Navigation program: Psychosocial Distress Screening Tool : Commission on Cancer Standard
More informationCare and support. for younger women with breast cancer. The breast cancer support charity
Care and support for younger women with breast cancer The breast cancer support charity When you re young, breast cancer is often the last thing you expect to have to think about. A diagnosis may feel
More information2012 AAHPM & HPNA Annual Assembly
Disclosure Patient Navigation Interventions To Improve Palliative Care For The Underserved: Integrating The Voice Of The Community And Scientific Rigor Drs. Fischer and Hauser have no relevant financial
More informationGuidelines and real World: Management of CML in chronic and advanced phases. Carolina Pavlovsky. FUNDALEU May 2017 Frankfurt
Guidelines and real World: Management of CML in chronic and advanced phases Carolina Pavlovsky. FUNDALEU 26-28 May 217 Frankfurt Some Issues in CML 217 First Line treatment: Imatinib vs 2nd generation
More informationChronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 GDHC1088CFR / Published April 2013 Executive Summary Sales for CML in Japan The Japan CML therapeutics market in the 7MM is
More informationAdherence Concepts for the Cancer Patient. Benyam Muluneh, PharmD, BCOP, CPP
Adherence Concepts for the Cancer Patient Benyam Muluneh, PharmD, BCOP, CPP Objectives Discuss the shift from intravenous to oral chemotherapy over the past few decades Assess the various dimensions of
More informationPatient Engagement: The Dilemma of Poor Adherence to Blood Pressure Medications
Patient Engagement: The Dilemma of Poor Adherence to Blood Pressure Medications William H. Polonsky, PhD, CDE May 15, 2014 whp@behavioraldiabetes.org Mr. Reynolds Age 59, divorced, self-employed CPA T2D
More informationOral Therapies: Strategies to Ensure Adherence Jan Tipton, MSN, RN, AOCN University of Toledo Medical Center
Oral Therapies: Strategies to Ensure Adherence Jan Tipton, MSN, RN, AOCN University of Toledo Medical Center Learning Objectives Review strategies, tools, and resources to facilitate adherence among patients
More informationThe American healthcare system, particularly the managed
REPORTS Collaborative Care and Motivational Interviewing: Improving Depression Outcomes Through Patient Empowerment Interventions Bill Anderson, PharmD The American healthcare system, particularly the
More informationRole of the Clinical Pharmacist in Primary Care
Role of the Clinical Pharmacist in Primary Care Amy Kramer, Pharm.D., Manager Clinical Pharmacy Services Kaiser Permanente Holly Miller, Pharm.D., BCACP, Primary Care Clinical Pharmacist Kaiser Permanente
More informationOverview of CML related sessions at 21 th EHA Meeting in Copenhagen Preliminary Program
Overview of CML related sessions at 21 th EHA Meeting in Copenhagen Preliminary Program Time slots Sessions Location June 9 th (Thursday) 8.00 10.00 Satellite Symposium: Improving outcomes: individualising
More informationCML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML
1 CML 2012 LLS Jan 26, 2012 David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML 2012 Current treatment options for CML patients Emerging therapies for CML treatment
More informationSynribo (Chronic Myeloid Leukemia)
Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 GDHC1141DFR / Published May 2013 Executive Summary Synribo (omacetaxine mepesuccinate): Key Metrics in CML Markets 2012 Synribo Sales
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tasigna) Reference Number: CP.PHAR.76 Effective Date: 09.01.11 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Bosulif) Reference Number: CP.PHAR.105 Effective Date: 10.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationCML HORIZONS 101 AND CML 101
CML HORIZONS 101 AND CML 101 by Pat Garcia-Gonzalez, USA May 1, 2015 Barcelona, Spain Goals of this Session Everything you ever wanted to know and were afraid of asking Help you navigate the conference
More informationUpdate on Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia
Update on Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia Chronic myelogenous leukemia (CML), a hematologic malignancy associated with a chromosomal mutation commonly known as the Philadelphia
More informationCML: Living with a Chronic Disease
CML: Living with a Chronic Disease Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia M. D. Anderson Cancer Center Houston, Texas Survival in Early Chronic Phase CML TKI Interferon Chemotherapy
More informationLinking Patients and Clinicians to Improve the Quality of Care in Asthma Control [B03 ]
Linking Patients and Clinicians to Improve the Quality of Care in Asthma Control [B03 ] Best-practice CME/CPD Case Study in Coproduction of Health By Kathleen Moreo, RN, BSN, BHSA, CCM, Cm, CDMS Tamar
More informationAdherence to therapy. Kamlesh Khunti University of Leicester, UK. William Polonsky University of California San Diego, USA
Adherence to therapy Kamlesh Khunti University of Leicester, UK William Polonsky University of California San Diego, USA 1 Dualities of interest Kamlesh Khunti: Honoraria for speaking, advising or research
More informationThe concept of TFR (Treatment Free Remission) in CML
The concept of TFR (Treatment Free Remission) in CML Giuseppe Saglio University of Turin, Italy What can we expect today on long-term therapy with TKIs in CML? German CML study IV Relative and overall
More informationClinical Policy: Nilotinib (Tasigna) Reference Number: CP.CPA.162 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Tasigna) Reference Number: CP.CPA.162 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationTraining for Memory Screeners
Training for Memory Screeners AFA s National Memory Screening Program Josie DiChiara, Senior Vice President of External Relations, jdichiara@alzfdn.org Lauren Totaro, National Program Coordinator, ltotaro@alzfdn.org
More information2nd generation TKIs to first line therapy
New Horizons 2011 Newly diagnosed CML moving 2nd generation TKIs to first line therapy Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA
More informationThe Un-Special World of Specialty Medications
The Un-Special World of Specialty Medications Manpreet Chahal, PharmD, PhD Oncology Pharmacist, Medical Oncology Associates, Spokane WA Adjunct Clinical Instructor, WSU College of Pharmacy mschahal@wsu.edu
More informationOncology Financial Navigation
Oncology Financial Navigation Stephanie Boecher MSN - Director of Oncology & Neuroscience Services Rachel Faustner BBA Oncology Financial Navigator Advocate Sherman Hospital Cancer Center Financial Toxicity
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More informationThe use of telehealth (text messaging and video communications) in patients with cystic fibrosis: A pilot study
The use of telehealth (text messaging and video communications) in patients with cystic fibrosis: A pilot study Dr. Michal Gur Rambam Health Care Campus Annual Israeli CF Society Conference November 2016
More informationADHERENCE TO TREATMENT
ADHERENCE TO TREATMENT Understanding and supporting patients John Weinman & Zoe Moon King s College London OVERVIEW OF TALK - The Adherence problem and its effects - Adherence issues in cancer treatment
More informationStarting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019
Starting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019 Disclosures Richard A. Larson, MD Research funding to the University
More informationRESEARCH ARTICLE. Introduction. Methods Wiley Periodicals, Inc.
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase AJH Dennis (Dong Hwan) Kim, 1 * Nada Hamad,
More informationJustifying New Oncology Pharmacist Positions
Faculty Disclosures Justifying New Oncology Pharmacist Positions I will not be discussing off-label uses of any medications I am on the speaker s bureau for Millenium Pharmaceuticals and am a paid consultant
More informationQuality of Life in Patients with Chronic Myeloid Leukemia
Quality of Life in Patients with Chronic Myeloid Leukemia Fabio Efficace, PhD Chairman GIMEMA WP Quality of Life Head, Health Outcomes Research Unit Italian Group for Adult Hematologic Diseases (GIMEMA)
More informationOriginal Study. Abstract
Original Study The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting Nicholas J. Di Bella,
More informationQuestionnaire on Quality of Life of Chinese CML Patients. Tyrosine kinase inhibitors (TKIs) have dramatically changed the history of
Supplementary material Questionnaire on Quality of Life of Chinese CML Patients Tyrosine kinase inhibitors (TKIs) have dramatically changed the history of chronic myelogenous leukemia (CML) treatment.
More informationMedication History. Case 1. Case 1. Case 2. Case 1. Four components of prescribing. Charles Mitchell
Medication History Charles Mitchell Director CSEP, University of Queensland Four components of prescribing Information gathering Clinical decision making Monitor and review Communicate decision - prescribe
More informationHow I treat high risck CML
Torino, September 14, 2018 How I treat high risck CML Patrizia Pregno Hematology Dept. Citta della Salute e della Scienza Torino Disclosures Advisory Board: Novartis, Pfizer, Incyte Speaker Honoraria:
More informationPonatinib Withdrawal Update
Hello. This is Dr. Stuart Goldberg from the Leukemia Division at the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, New Jersey. I am speaking on behalf of ManagingCML.com
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationBroward Health s Breast Cancer Navigation Program Meeting the needs of underserved patients
Broward Health s Breast Cancer Navigation Program Meeting the needs of underserved patients by Pia Delvaille, ARNP, MSN Broward Health, a nonprofit community health system, is one of the ten largest public
More informationPractice Advisory on Drug Coverage Parity across Medical and Pharmacy Benefits
Practice Advisory on Drug Coverage Parity across Medical and Pharmacy Benefits Introduction Oncology medications have historically been administered intravenously in a physician s office, infusion center
More informationc o m m u n i t y o u t r e a c h
c o m m u n i t y o u t r e a c h p r o g r a m knowledge of health care issues health education series Marion General Hospital s health education series consists of a kit with lesson plans and curriculum,
More informationSafety Connections Detecting and assessing suicidal ideation and risk in secondary care. Dr Jane Hutton & Anna Simpson
Safety Connections 2017 Detecting and assessing suicidal ideation and risk in secondary care Dr Jane Hutton & Anna Simpson Contact us: imparts@kcl.ac.ukac Find us: www.kcl.ac.uk/iop/depts/pm/research/imparts
More informationNEWS FROM. Roswell Park s LEUKEMIA SERVICE
NEWS FROM Roswell Park s LEUKEMIA SERVICE MEET THE LEUKEMIA TEAM The Leukemia Service at Roswell Park Cancer Institute (RPCI) is dedicated to quality patient care, innovative research, and the development
More informationWhere Debate & Discussion Translate to Breakthroughs. Now Offering 2 Locations. Greatdebatesinhema.com
Part of the Oncology Learning Network Now Offering 2 Locations March 22 23, 2019 Marina del Rey Marriott Marina del Rey, California April 5 6, 2019 Crowne Plaza Times Square Manhattan, New York Where Debate
More informationStudying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY)
A service of the U.S. National Institutes of Health Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY) This study is currently recruiting participants.
More informationIncreasing Cancer Screening: One-on-One Education Breast Cancer
Increasing Cancer Screening: One-on-One Education Breast Cancer Summary Evidence Table Studies from the Updated Search Abood et al. (2005) NR Other design w comparison group Mammography; Record review
More informationOncology Nursing Society Registry in Collaboration with CE City 2015 Performance Measure Specifications
1 ONSQIR 1 Non-PRQS Measure Oncology Nursing Society Registry in Collaboration with CE City 2015 Performance Measure Specifications Performance Measure Name: Symptom Assessment 1-o1a Symptom Assessment
More informationATS 2013 International Conference May Philadelphia Pennsylvania
American Journal of Respiratory and Critical Care Medicine American Journal of Respiratory Cell and Molecular Biology Proceedings of the American Thoracic Society STEPHEN C. CRANE, PhD, MPH Executive Director
More informationImproving Type 2 Diabetes Therapy Adherence and Persistence in the United States
July 2016 Improving Type 2 Diabetes Therapy Adherence and Persistence in the United States Appendix PATIENT ACTIVATION Introduction This Appendix document provides supporting material for the report entitled
More informationBosulif. Bosulif (bosutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review
More informationOverview of CML related sessions at 23 rd EHA Meeting in Stockholm
Overview of CML related sessions at 23 rd EHA Meeting in Stockholm Time slots Sessions Location June 14th (Thursday) 8.00 10.00 Satellite Symposium: Targeting the individual: Personalized treatment in
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationCML Treatment Failure: More Threatening Than It Appears. Mutation Testing
CML Treatment Failure: More Threatening Than It Appears Mutation Testing Content Mutations and treatment failure Single mutations Compound mutations Mutation testing Guideline recommendations Summary 2
More informationNAVIGATING THE HEALTH CARE SYSTEM. Floyd Shewmake, MD Senior Medical Director Coventry Health Care
NAVIGATING THE HEALTH CARE SYSTEM Floyd Shewmake, MD Senior Medical Director Coventry Health Care Topics of Discussion Choosing the right doctor Communications Managing your pharmacy benefits Compliance
More informationAssessing the Status of BRCA Testing and the Challenges Faced by Cancer Care Teams in the Community
Assessing the Status of BRCA Testing and the Challenges Faced by Cancer Care Teams in the Community Summary of Survey Findings April 2018 In March 2018, the Association of Community Cancer Centers (ACCC)
More informationManaging Older Patients With Lymphoma and Multiple Myeloma
2006 ONS Congress Webcast Evaluation Form Managing Older Patients With Lymphoma and Multiple Myeloma Session length: 1 hour, 45 minutes Contact hours: 1.5 Pharmacology hours offered: 15 minutes How to
More informationWelcome & Introductions
Living with Hodgkin Lymphoma Welcome & Introductions Dr. Lamar s slides are available for download at www.lls.org/programs, under the program listing. 1 Living with Hodgkin Lymphoma Living with Hodgkin
More informationHealthcare Transformation: Translating Aspiration into Action. Charlotte Yeh, MD Chief Medical Officer, AARP Services, Inc.
Healthcare Transformation: Translating Aspiration into Action Charlotte Yeh, MD Chief Medical Officer, AARP Services, Inc. The Healthcare Transformation Mission: Deliver on the promise of quality care
More informationThursday, April 23. Incorporating ClinicalTrials.gov Into Patient Education and Care Coordination. Session 1:30 3 pm Valencia BC
Session 1:30 3 pm Valencia BC Incorporating ClinicalTrials.gov Into Patient Education and Care Coordination Clinical trials play a significant role in improving cancer treatment, symptom management, and
More informationReal World Evidence in the Treatment of Ovarian Cancer. Elizabeth Eisenhauer MD FRCPC Queen s University
Real World Evidence in the Treatment of Ovarian Cancer Elizabeth Eisenhauer MD FRCPC Queen s University Outline What is real world evidence (RWE) and how can it shape policy and practice? In ovarian cancer,
More informationCancer Center Services Guide
Cancer Center Services Guide A Place of Hope and Healing Since 1999, the Robert and Carol Weissman Cancer Center at Martin Health has combined medical expertise with advanced technology for the most promising
More informationDeveloping and Implementing Standards for Psychosocial Care of Adults with Cancer
Developing and Implementing Standards for Psychosocial Care of Adults with Cancer Paul Jacobsen, Ph.D. Division of Population Science Moffitt Cancer Center Tampa, Florida March 10, 2015 Overview Describe
More informationSESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
SESSION III: Chronic myeloid leukemia PONATINIB Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Ponatinib A Pan-BCR-ABL Inhibitor Rationally designed inhibitor of BCR- ABL
More informationPediatric Adherence for the School Nurse
Pediatric Adherence for the School Nurse Eve-Lynn Nelson, Ph.D. Assistant Director, Research KU Center for TeleMedicine (913) 588-2413; enelson2@kumc.edu Generously sponsored through a grant from the Health
More information62 accc-cancer.org January February 2016 OI
62 accc-cancer.org January February 2016 OI BY TRICIA STRUSOWSKI, MS, RN, AND JEREMY STAPP, MBA Patient Navigation Metrics Measuring the impact of your patient navigation services The Oncology Nursing
More informationMoving Forward. Support for you after a diagnosis of breast cancer. The breast cancer support charity
Moving Forward Support for you after a diagnosis of breast cancer The breast cancer support charity We understand breast cancer changes everything. If you ve had treatment for breast cancer and are looking
More informationObjectives. Survivors. Survivorship in Cancer 7/20/2018. Over 15 million survivors in the U.S. Over 32 million worldwide. Oncology Survivorship Care
Survivorship in Cancer Oncology Survivorship Care Kathleen Martin, FNP-BC, AOCNP Objectives Define population of survivors of cancer Define the need for survivorship care Explain the purpose of survivorship
More informationGenetic Testing Program for Huntington s Disease
Genetic Testing Program for Huntington s Disease Genetic testing for the Huntington s Disease (HD) gene expansion became possible in 1993. This test can be used to confirm the diagnosis in someone who
More informationMRD in CML (BCR-ABL1)
MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:
More informationNCI Community Cancer Centers Program
NCI Community Cancer Centers Program BIOSPECIMENS SURVIVORSHIP Andrew L. Salner, MD FACR Director, Helen & Harry Gray Cancer Center Hartford Hospital Hartford, CT Hartford Hospital 865 bed community and
More informationWhat is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR
What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR after 18 months of imatinib? Second generation TKIs as a bridge to allogeneic SCT
More informationEvaluation of a Computer-Based Toolkit for Hematological Cancer Patients, Caregivers, and Family/Friends
Evaluation of a Computer-Based Toolkit for Hematological Cancer Patients, Caregivers, and Family/Friends Presented by Doug Rupert, MPH; Cindy Soloe, MPH; Erika Willacy, MPH; Tania Fitzgerald, BA; David
More informationHELPING RESHAPE SHARED DECISION MAKING WITH THE DIABETES MEDICATION OPTIONS DECISION AID
HELPING RESHAPE SHARED DECISION MAKING WITH THE DIABETES MEDICATION OPTIONS DECISION AID The Diabetes Decision Aid is favorably reviewed by the AADE and featured on the Together 2 Goal website. DIABETES
More informationExecutive summary Overview
Executive summary Overview In this appraisal, we have demonstrated that dasatinib is clinically more effective, as well as more cost effective, than imatinib, the current standard of care. In the pivotal
More informationHepCure : An innovative web-based toolkit to support the treatment of hepatitis C at community health centers in New York State
HepCure : An innovative web-based toolkit to support the treatment of hepatitis C at community health centers in New York State CHCANYS 15: Statewide Conference & Clinical Forum October 19, 2015 Jeffrey
More information